DK1150704T3 - Melagatran til behandling af betændelse - Google Patents

Melagatran til behandling af betændelse

Info

Publication number
DK1150704T3
DK1150704T3 DK00902232T DK00902232T DK1150704T3 DK 1150704 T3 DK1150704 T3 DK 1150704T3 DK 00902232 T DK00902232 T DK 00902232T DK 00902232 T DK00902232 T DK 00902232T DK 1150704 T3 DK1150704 T3 DK 1150704T3
Authority
DK
Denmark
Prior art keywords
melagatran
inflammation
treatment
prodrug
medicament
Prior art date
Application number
DK00902232T
Other languages
Danish (da)
English (en)
Inventor
Ian Kirk
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1150704T3 publication Critical patent/DK1150704T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DK00902232T 1999-01-13 2000-01-13 Melagatran til behandling af betændelse DK1150704T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900070A SE9900070D0 (sv) 1999-01-13 1999-01-13 New use

Publications (1)

Publication Number Publication Date
DK1150704T3 true DK1150704T3 (da) 2006-06-12

Family

ID=20414074

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00902232T DK1150704T3 (da) 1999-01-13 2000-01-13 Melagatran til behandling af betændelse

Country Status (20)

Country Link
US (3) US6683054B1 (pt)
EP (1) EP1150704B1 (pt)
JP (1) JP2002534477A (pt)
KR (1) KR100701539B1 (pt)
CN (1) CN1170592C (pt)
AT (1) ATE319473T1 (pt)
AU (1) AU767077B2 (pt)
BR (1) BR0007452A (pt)
CA (1) CA2356611A1 (pt)
CY (1) CY1107465T1 (pt)
DE (1) DE60026491T2 (pt)
DK (1) DK1150704T3 (pt)
ES (1) ES2257282T3 (pt)
IL (1) IL143985A0 (pt)
NO (1) NO20013414D0 (pt)
NZ (1) NZ512713A (pt)
PT (1) PT1150704E (pt)
SE (1) SE9900070D0 (pt)
WO (1) WO2000041716A1 (pt)
ZA (1) ZA200105275B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101762D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab New use
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
SE0103590D0 (sv) * 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
SE0203349D0 (sv) * 2002-11-12 2002-11-12 Astrazeneca Ab New use
WO2011126903A2 (en) 2010-03-30 2011-10-13 Verseon, Inc. Multisubstituted aromatic compounds as inhibitors of thrombin
NZ711064A (en) 2013-03-15 2019-06-28 Verseon Corp Pyridone-substituted pyrazolyl compounds as serine protease inhibitors
CN110423221A (zh) 2013-03-15 2019-11-08 维颂公司 作为凝血酶抑制剂的卤代吡唑
WO2016044662A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
HUE060104T2 (hu) 2015-02-27 2023-01-28 Verseon Int Corporation Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok
JP2021531338A (ja) 2018-07-13 2021-11-18 ヴァーセオン インターナショナル コーポレイション トロンビン阻害薬、製剤、及びそれらの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9600216D0 (sv) * 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
US5669754A (en) * 1996-04-22 1997-09-23 Advanced Dynamics Corporation Ltd. Method and apparatus for collecting plates
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
JP2002525298A (ja) 1998-09-28 2002-08-13 メルク エンド カムパニー インコーポレーテッド トロンビン阻害剤の投与による炎症疾患の処置法
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.

Also Published As

Publication number Publication date
JP2002534477A (ja) 2002-10-15
ES2257282T3 (es) 2006-08-01
BR0007452A (pt) 2001-10-16
US6683054B1 (en) 2004-01-27
EP1150704A1 (en) 2001-11-07
WO2000041716A1 (en) 2000-07-20
AU2336100A (en) 2000-08-01
DE60026491D1 (de) 2006-05-04
CY1107465T1 (el) 2012-12-19
CA2356611A1 (en) 2000-07-20
IL143985A0 (en) 2002-04-21
ATE319473T1 (de) 2006-03-15
AU767077B2 (en) 2003-10-30
KR20010101492A (ko) 2001-11-14
KR100701539B1 (ko) 2007-03-30
NO20013414L (no) 2001-07-10
NO20013414D0 (no) 2001-07-10
US20080058303A1 (en) 2008-03-06
US20040082518A1 (en) 2004-04-29
EP1150704B1 (en) 2006-03-08
DE60026491T2 (de) 2006-11-02
NZ512713A (en) 2004-10-29
CN1341028A (zh) 2002-03-20
SE9900070D0 (sv) 1999-01-13
CN1170592C (zh) 2004-10-13
PT1150704E (pt) 2006-06-30
ZA200105275B (en) 2002-09-26

Similar Documents

Publication Publication Date Title
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
DK1404331T3 (da) Sustained release-formuleringer af oxymorphon
JO2282B1 (en) Oxazole derivatives
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
SE0101932D0 (sv) Pharmaceutical combinations
ATE410426T1 (de) Heterocyclische verbindungen alsccr5-antagonisten
SE9802208D0 (sv) Novel compounds
PL351710A1 (en) Anti−inflammatory therapy for inflammatory mediated infection
DE60128100D1 (de) Analgetisches arzneimittel
IS6130A (is) Bólgueyðandi meðhöndlun fyrir bólgu tengt smit
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
SE9802209D0 (sv) Novel compounds
SE0200198D0 (sv) New use
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
ATE350064T1 (de) Pharmazeutische zusammensetzungen von rapamycines
SE0004827D0 (sv) Therapeutic compounds
SE0300535D0 (sv) Treatment of burns
DK1490049T3 (da) Citalopram til behandling af forhöjet blodtryk
DK1399141T3 (da) Anvendelse af acetyl L-carnitin til fremstilling af et lægemiddel til forebyggende terapi af post-kirurgisk smerte
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
SE0101762D0 (sv) New use
SE9900438D0 (sv) The pharmacological use of certian cystine derivatives